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Abstract
Background
Overexpression of human epidermal growth factor receptor 2 (HER2) is observed in approx-
imately 15–23% of breast cancers and these cancers are classified as HER2-positive breast
cancer. Trastuzumab is the first-line targeted therapeutic drug for HER2-positive breast can-
cer and has improved patient overall survival. However, acquired resistance to trastuzumab
is still a critical issue in breast cancer treatment. We previously established a trastuzumab-
resistant breast cancer cell line (named as BT-474-R) from a trastuzumab-sensitive HER2-
amplified cell line BT-474. Lapatinib is also a molecular-targeted drug for HER2-positive
breast cancer, which acquired the resistance to trastuzumab. Acquired resistance to lapati-
nib is also an issue to be conquered.
Methods
We established trastuzumab/lapatinib-dual resistant cell line (named as BT-474-RL2) by
additionally treating BT-474-R with lapatinib. We analyzed the mechanisms of resistance to
trastuzumab and lapatinib. Besides, we analyzed the effect of the detected resistance
mechanism in HER2-positive breast cancer patients.
Results
Proto-oncogene tyrosine-protein kinase Yes1, which is one of the Src family members, was
amplified, overexpressed and activated in BT-474-R and BT-474-RL2. Silencing of Yes1 by
siRNA induced both BT-474-R and BT-474-RL2 to restore the sensitivity to trastuzumab
and lapatinib. Pharmaceutical inhibition of Yes1 by the Src inhibitor dasatinib was also
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effective to restore the sensitivity to trastuzumab and lapatinib in the two resistant cell lines.
Combination treatment with dasatinib and trastuzumab induced down-regulation of signal-
ing molecules such as HER2 and Akt. Moreover, the combination treatments induced G1-
phase cell-cycle arrest and apoptosis. Consistent with cell line data, high expression of
Yes1 mRNA was correlated with worse prognosis in patients with HER2-positive breast
cancer.
Conclusion
Yes1 plays an important role in acquired resistance to trastuzumab and lapatinib in HER2-
positive breast cancer. Our data suggest that pharmacological inhibition of Yes1 may be an
effective strategy to overcome resistance to trastuzumab and lapatinib.
Introduction
Breast cancer is one of the most frequent malignancies for women in many countries [1–3].
Breast cancers are heterogeneous diseases, and are classified by the molecular characteristics.
There are 5 intrinsic breast cancer subtypes: luminal A, luminal B, normal breast-like, human
epidermal growth factor receptor 2 (HER2)-enriched, and basal-like, each unique in incidence,
survival and response to the therapy [4].
HER2 is one of the receptor tyrosine kinases (RTK) comprising the HER protein family,
and is located in the cell membrane [5]. HER family proteins, epidermal growth factor recep-
tor (EGFR, HER1), HER3 and HER4 form heterodimers or homodimers following the activa-
tion by their ligands, and consequently, their dimerization leads to the activation of the
downstream signaling such as the PI3K-Akt and MAPK signaling pathways, resulting in cell
proliferation and survival [6]. The HER2-associated dimers generate the most powerful signal-
ing for cellular transformation [7]. However, HER2 is known to have no ligands and forms the
dimers in ligand-independent manner [7]. Thus, overexpression of HER2 is considered to be
the oncogenic-driver in several malignancies including breast, gastric, esophageal and ovarian
cancers [8, 9].
Trastuzumab is a first-line therapeutic drug for HER2-positive breast cancer, and the addi-
tion of trastuzumab to chemotherapy was associated with a higher rate of objective response, a
longer duration of response and survival [10]. However, the acquired resistance to trastuzu-
mab is known to be observed in most of the treated cases within one year after the treatment
starts [11] and overcoming the acquired resistance to trastuzumab is one of the major clinical
issues contributing to mortality of women. To date, various mechanisms of the acquired resis-
tance to trastuzumab are reported such as the activation of other RTKs including EGFR,
HER3, HER4 and MET [12, 13], the activation of the downstream signaling of HER2 [12, 13],
T798M mutation in HER2 gene [14], PIK3CA mutations [15], the activation of Src [16, 17], the
expression of p95HER2 [12, 18], the elevated expression of Hsp90 [19], reduced expression of
PTEN [15, 20], the expression of MUC4 [12, 13, 21], and the inhibition of miR200c [22].
To understand the molecular basis for resistance to HER2-targeted therapies, we previously
established a trastuzumab-resistant breast cancer cell line (named as BT-474-R) from a trastu-
zumab-sensitive cell line with HER2 amplification (BT-474) by treating BT-474 cells with
increasing doses of trastuzumab [23]. Analysis showed that nuclear factor-kappa B (NF-kap-
paB) was constitutively activated in the BT-474-R cells mimicking the phenotype of basal-like
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breast cancers. Pharmacologic inhibition of NF-kappaB improved sensitivity of BT-474-R cells
to trastuzumab. However, inhibition of NF-kappaB with trastuzumab alone was inadequate to
sensitize BT-474-R cells, indicating that there may be other unidentified mechanisms mediat-
ing the acquired resistance to trastuzumab.
Lapatinib is the first dual kinase inhibitor of EGFR and HER2 tyrosine kinases [24]. This
drug is used to treat HER2-positive breast cancer with acquired resistance to trastuzumab [25].
Acquired resistance to lapatinib is also an emerging issue in clinical management of breast
cancer patients. As lapatinib is administered to HER2-positive breast cancers with acquired
resistance to trastuzumab in clinical setting, it is valuable to establish a trastuzumab/lapatinib-
dual resistant cell line from a trastuzumab-resistant cell line.
In the current study, we established the trastuzumab/lapatinib-dual resistant cell line
(named as BT-474RL2) from BT-474-R, in order to elucidate the mechanism of the acquired
resistance to trastuzumab and lapatinib, and to overcome the resistance.
Materials and methods
Ethics statement
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was
approved by the Animal Care and Use Committee of Okayama University (Permit Number:
OKU-2014635). All surgery was performed under ketamine and xylazine anesthesia, and all
efforts were made to minimize suffering. Detailed method for the animal experiments is
described in S1 Method.
Cell lines and reagents
HER2-positive human breast cancer cell line BT-474 (catalog number: HTB-20) was pur-
chased from American Type Culture Collection (Manassas, VA, USA). BT-474-R was previ-
ously established by treating BT-474 with increasing doses of trastuzumab (from 0.1 μg/mL to
40 μg/mL) for 10 months [23]. To obtain trastuzumab/lapatinib-dual resistant BT-474 (named
as BT-474-RL2), BT-474-R was additionally treated with increasing doses of lapatinib (from
0.1 μM to 5 μM) for 6 months. The cells were maintained in Dulbecco’s modified Eagle
medium (DMEM) with 10% fetal bovine serum at 5% CO2 under 37˚C. Trastuzumab was pur-
chased from Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan). Lapatinib was purchased from
Cayman Chemical Company (Ann Arbor, MI, USA) and dasatinib was purchased from Bris-
tol-Myers Squibb Company (New York, NY, USA).
Cell viability assay
Cell proliferation was determined by CellTiter 961 AQueous One Solution Cell Proliferation
Assay (Promega, Fitchburg, WI, USA). Cells (3,000/well) were seeded in 96-well plates and
then the medium in the wells was replaced with the medium containing diluted drug solutions
of trastuzumab, lapatinib, dasatinib or their combinations in a 4-log range or complete
medium, which were distributed in 8-replicate wells. Cells were incubated in the presence of
each concentration of the respective drugs for 72 hours at 37˚C in a humidified atmosphere of
5% CO2 in air. After that, MTS dye was added to each well. The cultures were incubated for
another 1 hour at 37˚C in a humidified atmosphere with 5% CO2. Optical densities of samples
were measured at 492 nm using Multiskan™ FC Microplate Photometer (Thermo Fisher Scien-
tific, Waltham, MA, USA). Mean optical density at each drug concentration was calculated
after discarding the highest and lowest values. The anti-tumor effects of respective drugs for
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each cell line were shown in terms of inhibitory concentration at 25% (IC25) for trastuzumab
or 50% (IC50) lapatinib, which was determined by plotting the graph of percentage of cell
growth inhibition (Y-axis) versus drug concentration (X-axis). IC25 and IC50 values were
expressed as mean and standard errors (SE). The assays were repeated more than three times.
HER2 expression in BT-474 and its sublines
The expression of HER2 was determined by flow cytometry. The cells were harvested, washed
and fixed by 4% formaldehyde for 10 min at 37˚C. In the primary reaction, the cells were
treated with either no antibody or anti-HER2 antibody (Cell Signaling Technology, Beverly,
MA, USA) for 1 hour at 25˚C. After washing, the cells were treated with Alexa Fluor 1-488-
conjugated secondary antibody (Cell Signaling Technology) for 30 min at 25˚C. After washing,
the cells were analyzed using BD FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA).
The cell population was gated on forward scatter and side scatter. The HER2 expression analy-
sis was performed with CellQuest version 3.1 (BD Biosciences).
Western blotting
Cells were washed in ice-cold PBS and lysed in RIPA buffer (Sigma-Aldrich, St. Louis, MO,
USA). Cell lysate was collected after centrifugation at 15,000 rpm for 15 min at 4˚C. Protein
was quantitated using DC™ protein assay (Bio-Rad Laboratories, Hercules, CA, USA), fraction-
ated on SDS-PAGE and blotted onto a membrane using Trans-Blot1 Turbo™ Transfer System
(Bio-Rad Laboratories). After the membrane was blocked with 5% skim milk in TBS-contain-
ing 0.05% Tween 20 (T-TBS) for 1 hour, it was probed with various the primary antibodies
overnight at 4˚C, followed by the incubation with the secondary antibodies for 1 hour at 25˚C.
Proteins were detected using ECL Prime Western Blotting Detection Reagent (General Electric
Company, Fairfield, CT, USA) and by scanning the membrane using ImageQuant LAS 4000
(General Electric Company). The antibodies used were as follows: phospho-EGFR-Tyr1068
(rabbit monoclonal antibody, catalog number: 2234S, dilution, 1:1000, Cell Signaling Technol-
ogy), EGFR (rabbit monoclonal antibody, catalog number: 2085S, dilution, 1:1000, Cell Signal-
ing Technology), phospho-HER2-Tyr877 (rabbit monoclonal antibody, catalog number:
2241S, dilution, 1:1000, Cell Signaling Technology), HER2 (rabbit monoclonal antibody, cata-
log number: 2165S, dilution, 1:1000, Cell Signaling Technology), phospho-HER3-Tyr1289
(rabbit monoclonal antibody, catalog number: 4791S, dilution, 1:1000, Cell Signaling Technol-
ogy), HER3 (rabbit monoclonal antibody, catalog number: 4754, dilution, 1:1000, Cell Signal-
ing Technology), phospho-Akt-Ser473 (rabbit monoclonal antibody, catalog number: 4060S,
dilution, 1:1000, Cell Signaling Technology), Akt (rabbit monoclonal antibody, catalog num-
ber: 9272S, dilution, 1:1000, Cell Signaling Technology), phospho-MAPK-Tyr202/204 (rabbit
monoclonal antibody, catalog number: 9101, dilution, 1:1000, Cell Signaling Technology),
MAPK (rabbit monoclonal antibody, catalog number: 9102, dilution, 1:1000, Cell Signaling
Technology), phospho-Src family-Tyr416 (rabbit monoclonal antibody, catalog number: 2101,
dilution, 1:1000, Cell Signaling Technology), Src (rabbit monoclonal antibody, catalog num-
ber: 2109, dilution, 1:1000, Cell Signaling Technology), Yes1 (rabbit monoclonal antibody, cat-
alog number: 3201S, dilution, 1:1000, Cell Signaling Technology), Actin (mouse monoclonal
antibody, catalog number: MAB1501R, dilution, 1:5000, Merck Millipore, Darmstadt, Ger-
many), anti-rabbit IgG-HPR (goat monoclonal antibody, catalog number: sc-2030, dilution,
1:2000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-mouse IgG (goat monoclo-
nal antibody, catalog number: sc-2031, dilution, 1:2000, Santa Cruz Biotechnology).
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Gene expression assays by quantitative reverse transcription PCR
Total RNA was isolated using RNeasy mini Kit (Qiagen, Venlo, Netherlands) and reverse tran-
scribed with High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Wal-
tham, MA, USA). The quantitative reverse transcription PCR (q-RT-PCR) was performed on
StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific) using Power SYBR1 Green
PCR Master Mix (Thermo Fisher Scientific). The gene expression was calculated using delta-
delta CT method. Samples were analyzed in triplicate. GAPDH was used as an endogenous
control. Data were expressed as mean and SE. The assays were repeated three times. The prim-
ers used were as follows. GAPDH: (F) 5’-TCG GAG TCA ACG GAT TTG GTC-3’,(R) 5’-
AAA CCA TGT AGT TGA GGT CAA TG-3’, c-Src: (F) 5’-TGA AGA CAA TGA GTA CAC
GGC-3’,(R) 5’-CTTTGT GGT GAG CTC AGT CA-3’, Yes1: (F) 5’-GAG AAT CTT TGC
GAC TAG AGG-3’,(R) 5’-CTG GCA TCA TTG TAC CTG G-3’, Fyn: (F) 5’-CAC CGT
CTT TGG AGG TGT G-3’, (R) 5’-TCA TCT TCT GTC CGT GCT TC-3’, Fgr: (F) 5’-AAC
CCT GGC TTC CTT GAT AG-3’,(R) 5’-TTG GTG AAG GTG AGG TCA TC-3’, Lyn: (F)
5’-ATGTGA GAG ATC CAA CGT CC-3’, (R) 5’-TGC CAT CAT AGG GGT ACA AG-3’,
Lck: (F) 5’-TCC CAT AGT CCC ACT GGA TG-3’,(R) 5’-CTG TGC AGA GCG ATA ACC
AG-3’, Hck: (F) 5’-GGC CTA ATA GCC ACA ACA GC-3’,(R) 5’-TGA GGT CTT CGT
GGT GAA TG-3’, Blk: (F) 5’-CTT CAA CCA CCT TAC TCC TCC-3’,(R) 5’-AGG TCC
CGA TCA TTC ATA GC-3’, Frk: (F) 5’-CTG AGG ACA GAA GCC TAC AGG-3’,(R) 5’-
GGA ACC GGT CTT GTT TTC TG-3’.
Copy number assays by qPCR
DNA was isolated using DNeasy Blood & Tissue Kit (Qiagen). Copy number assays were
determined by qPCR using Power SYBR1 Green PCR Master Mix (Thermo Fisher Scientific).
The gene dosage was calculated using the standard curve method. Samples were analyzed in
triplicate. LINE-1 was used as a reference gene. Relative copy number of each sample was
determined by comparing the ratio of target gene to LINE-1 in each sample with the ratio of
these genes in Human Genomic DNA (HGD) (Merck Millipore). Data were expressed as
mean and SE. The assays were repeated three times. The primers used were as follows. LINE-1:
(F) 5’-AAA GCC GCT CAA CTA CAT GG-3’, (R) 5’-TGC TTT GAA TGC GTC CCA GAG-
3’, Yes1: (F) 5’-TTACGG AAT CAT GCC ACT C-3’, (R) 5’-CCCATG CCC AAT AAA
GTG-3’.
siRNA transfection
Small interfering RNAs (siRNAs) specific for Yes1 (Silencer1 Select Validated siRNA
#4390824) and non-targeting control (Silencer1 Select Negative Control No.2 siRNA
#4390846) were purchased from Thermo Fisher Scientific. Each siRNA was transfected to the
cells using Lipofectamine1 RNAiMAX Transfection Reagent (Thermo Fisher Scientific), incu-
bated for 48 hours according to the manufacturer’s instructions.
Clonogenic assay
Cells (1,000/well) were seeded in 6-well plates in triplicate. After the attachment to plastic sur-
face, cells were treated with trastuzumab (1 μg/mL) alone, dasatinib (100 nM) alone or the
combination of them for 14 days. After fixation by 4% formaldehyde, cells were stained using
0.2% crystal violet. Colony counts were measured using ImageJ version 1.48 (National Insti-
tutes of Health, Bethesda, MD).
Data were expressed as mean and SE. The assays were repeated three times.
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Soft agar colony formation assay
Cells (1,000/well) were suspended in 0.33% agar in DMEM with 10% fetal bovine serum and
layered over a 0.50% agar base in 6-well plates in triplicate followed by the treatment with tras-
tuzumab (1 μg/mL) alone, dasatinib (100 nM) alone or the combination of them for 24 hours.
After 14 days, the number of microscopically visible colonies (>30 cells) was counted. Data
were expressed as mean and SE. The assays were repeated three times.
Cell-cycle analysis
Cells were seeded in 6-well plates. After attachment to plastic surface, cells were treated with
trastuzumab (1 μg/mL) alone, dasatinib (100 nM) alone or their combination for 24 hours.
The cell cycle distribution was assessed using a propidium iodide staining-based assay with the
Cycletest™ Plus DNA Reagent Kit (BD Biosciences) and FACSCaliber (BD Biosciences). The
cell cycle analysis was performed with CellQuest version 3.1 (BD Biosciences). Data were
expressed as mean and SE. The assays were repeated three times.
Apoptosis analysis
Cells were seeded in 6-well plates. After attachment to plastic surface, cells were treated with
trastuzumab (1 μg/mL), dasatinib (100 nM) or their combination for 48 hours. And then cell
lysate was collected for western blot analysis. The level of cleaved PARP was examined using
the antibody for cleaved PARP (mouse monoclonal antibody, catalog number: 9546S, dilution,
1:2000, Cell Signaling Technology).
Bioinformatic analysis
Messenger RNA profiling for 236 breast cancer patients (GSE3494) and 204 breast cancer
patients with relapse (GSE12276) were obtained from GEO (http://www.ncbi.nlm.nih.gov/
geo/). Briefly, patients were divided into low and high expression group of HER2 or Yes1
mRNA, based on the median expression value of all the patients within the dataset, respec-
tively. Disease-specific survival (DSS) of the cases with higher expression of Yes1 was com-
pared to that of the cases with lower expression of Yes1 for the patients with higher expression
of HER2 in GSE3494 dataset, while relapse-free survival (RFS) was compared using GSE12276
dataset with higher expression of HER2.
Statistical analysis
All the statistical analyses in this study were performed using EZR version 1.32 (Saitama Medi-
cal Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R
version 3.2.2 (The R Foundation for Statistical Computing, Vienna, Austria) [26]. Specifically,
the software is a modified version of R commander designed to add statistical functions fre-
quently used in biostatistics. The difference was compared using one-way analysis of variance
(multiple groups) or t-test (two groups). The disease-specific survival (DSS) or relapse-free
survival (RFS) was calculated using two different cohorts. The survival curve was calculated by
the Kaplan—Meier method and the difference between groups was compared with the log-
rank test. A value of P< 0.05 was considered statistically significant.
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Results
Characterization of trastuzumab-resistant cell line BT-474-R and
trastuzumab/lapatinib-dual resistant cell line BT-474-RL2
Parental BT-474 cell line and established two cell lines BT-474-R and BT-474-RL2 were proven
to have the same genetic origins and were authenticated using GenePrint1 10 System (Pro-
mega). Morphological changes in the parental cell line and its sublines are shown in Fig 1A.
To confirm the resistance to trastuzumab and lapatinib, we performed the cell viability assay
(Fig 1B). The IC25 value of BT-474, BT-474-R and BT-474-RL2 for trastuzumab was
0.114 ± 0.0314, > 1000 and> 1000 μg/mL, respectively. As for lapatinib, the IC50 value of
them was 0.0178 ± 0.00285, 0.239 ± 0.0443 and 3.94 ± 0.225 μM, respectively (Table 1).
We next evaluated the expression of HER2 in cell surface among BT-474, BT-474-R and
BT-474-RL2 by flow cytometry. There was no significant difference of the expression of HER2
among them (Fig 2A). We also elucidated the expression of HER2-related signaling. In resis-
tant cell lines, the phosphorylation of HER2, Akt and Src family was upregulated. Phospho-
MAPK was downregulated in resistant cell lines (Fig 2B).
Fig 1. Establishment of trastuzumab-resistant cell line BT-474-R and trastuzumab/lapatinib-dual resistant cell line BT-474-RL2.
(A) Morphological changes in parental cell line (BT-474) and its sublines (BT-474-R and BT-474-RL2). (B) MTS assay evaluating cell
viability of BT-474, BT-474-R and BT-474-RL2 upon treatment with various concentrations of trastuzumab or lapatinib for 72 hours. Data
are shown as means ± standard errors (SE). The assay using trastuzumab was repeated five times, and the assay using lapatinib was
repeated three times.
doi:10.1371/journal.pone.0171356.g001
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Table 1. IC25 and IC50 values of BT-474 and its sublines.
Cell line Characteristics IC25 (mean ± SE) IC50 (mean ± SE)
Trastuzumab (μg/mL) Lapatinib (μM)
BT-474 HER2 amplification 0.114 ± 0.0314 0.0178 ± 0.00285
BT-474-R Trastuzumab-resistant subline > 1000 0.239 ± 0.0443
BT-474-RL2 Trastuzumab/lapatinib-resistant subline > 1000 3.94 ± 0.225
doi:10.1371/journal.pone.0171356.t001
Fig 2. Expression of HER2 and its related proteins. (A) Flow cytometric analysis of HER2 expression level on BT-474, BT-474-R and
BT-474-RL2. (B) Protein expression profile of BT-474, BT-474-R and BT-474-RL2. Phosphorylation of major cell signaling pathways
changes among BT-474, BT-474-R and BT-474-RL2.
doi:10.1371/journal.pone.0171356.g002
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Yes1 is upregulated in BT474-R and BT474-LR resistant cell lines
Because expression of Src family protein was increased in the resistant cell lines, we evaluated
mRNA expression of Src family proteins. Src family proteins consist of 9 members, that is, c-
Src, Yes, Fyn, Lyn, Fgr, Blk, Hck, Lck and Frk. mRNA expression of Yes1 was increased in the
resistant cell lines, especially in BT-474-RL2, compared to other Src family proteins (Fig 3A).
As for Fgr, Blk and Hck, the mRNA expression was not detected. To confirm the absence of
mRNA expression of them, Burkitt’s lymphoma cell line Daudi (catalog number: JCRB9071)
and histiocytic lymphoma cell line U937 (catalog number: JCRB9021) were used as positive
controls for Fgr, Blk and Hck and conventional RT-PCR was performed. mRNA expression of
Fgr, Blk and Hck was not detected in BT-474, BT-474-R or BT-474-RL2 (S1 Method, S1 Fig).
Next, we performed western blot analysis to evaluate the protein expression of Yes1. Expres-
sion of Yes1 protein was considerably elevated (Fig 3B). We also determined the copy number
Fig 3. Yes1, one of the Src family member, is a key molecule in acquired HER2-resistance. (A) Comparison of mRNA expression of
Src family members in BT-474, BT-474-R and BT-474-RL2 by q-RT-PCR. Fgr, Blk and Hck was not detected. Data are shown as means +
SE. The assay was repeated three times. (B) Western blot analysis of Yes1 protein expression among BT-474, BT-474-R and BT-474-
RL2. (C) Copy number assay of Yes1 in BT-474, BT-474-R and BT-474-RL2. Human Genomic DNA (HGD) was used as the control (2
copies). Data are shown as means + SE. The assay was repeated three times. (D) Protein expression profile after Yes1 knockdown by
Yes1 siRNA in BT-474, BT-474-R and BT-474-RL2. (E) MTS assay assessing the sensitivity to trastuzumab or lapatinib among BT-474,
BT-474-R and BT-474-RL2 after Yes1 knockdown. Cells (3,000/well) were seeded in 96-well plates and transfected with siRNA for 48
hours followed by the treatment of trastuzumab or lapatinib for 72 hours. Data are shown as means + SE. The assay was repeated three
times.
doi:10.1371/journal.pone.0171356.g003
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of Yes1. Copy number of Yes1 was gained in resistant cell lines (Fig 3C), which indicates the
cause of the elevated expression of Yes1 was at partially due to its increased copy number.
Effect of Yes1 in resistant cell lines
To clarify the effect of Yes1 in resistant cell lines, we performed siRNA-mediated knockdown
of Yes1. After the administration of siRNA of Yes1, the expression of Yes1 was significantly
inhibited. Predominant reduction of Yes1 protein resulted in the downregulation of phospho-
Src family, suggesting that the activation of phospho-Src family was due to the upregulation of
Yes1 (Fig 3D). We also confirmed that the effect of trastuzumab and lapatinib in the resistant
cell lines were recovered after knockdown of Yes1 (Fig 3E).
Effect of the Src inhibitor dasatinib in the resistant cell lines
Because Src family proteins, especially Yes1, was upregulated in the resistant cell lines, we
focused on the Src inhibitor dasatinib. To overcome the resistance to trastuzumab, we per-
formed the combination therapy of trastuzumab and dasatinib using cell viability assay and
colony formation assays (clonogenic assay and soft agar colony formation assay). In the resis-
tant cell lines, the combination of trastuzumab or lapatinib with dasatinib led to the additive
anti-tumor effect (Fig 4A, 4B and 4C). We also performed western blot analysis to elucidate
the effect of combination therapy to the HER2-related pathway. In BT-474-R and BT-474-
RL2, phosphorylation of Akt was more inhibited in the combination therapy than in the single
agent. Phosphorylation of HER2 was inhibited by dasatinib alone in all cell lines, which was
similar to the previous report [16] (Fig 4D).
Furthermore, we conducted cell-cycle analysis and apoptosis analysis to see the effect of
trastuzumab and dasatinib in resistant cell lines. Combination therapy induced G1 arrest
more (Fig 5A). Apoptosis was also induced after the combination of trastuzumab and dasati-
nib (Fig 5B).
Prognostic significance of Yes1 mRNA expression in patients with higher
expression of HER2 mRNA
We further investigated whether overexpression of Yes1 had any impact on clinicopathological
characteristics of breast cancers. To this end, we examined the associations of Yes1 mRNA
expression with prognosis of breast cancer patients using two independent datasets, such as
236 breast cancer patients with/without TP53 mutation (TP53 cohort, GSE3494) and 204
breast cancer patients with distant metastasis (metastasis cohort, GSE12276). Patients could be
divided into low and high expression groups of HER2 mRNA, as well as Yes1 mRNA, based on
the median expression value of all the patients within the dataset, respectively. In TP53 cohort
with higher expression of HER2 (n = 118), disease-specific survival (DSS) of the cases with
higher expression of Yes1 was significantly shorter than that of the cases with lower expression
of Yes1 (P = 0.0133, Fig 6A). Ten-year DSS rate for higher and lower expression of Yes1 was
59.8% and 83.6%, respectively. In addition, relapse free survival (RFS) of the cases with higher
expression of Yes1 was significantly shorter than that of the cases with lower expression of Yes1
(P = 0.0000546, Fig 6B) in metastasis cohort with higher expression of HER2 (n = 102). Three-
year RFS rate for higher and lower expression of Yes1 was 9.8% and 36.7%, respectively. These
findings suggest the cooperative expression of Yes1 and HER2 associates with poor prognosis
in breast cancer patients.
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Fig 4. Dasatinib, Src family inhibitor, overcomes HER2-resistance. (A) MTS assay evaluating the effect of
trastuzumab or lapatinib alone, dasatinib alone or the combination on BT-474, BT-474-R and BT-474-RL2. Data
are shown as means + SE. The assay was repeated three times. (B) Clonogenic assay evaluating the effect of
long-term exposure to trastuzumab alone, dasatinib alone or the combination of them on BT-474-R and BT-
474-RL2. Data are shown as means + SE. The assay was repeated three times. (C) Soft agar colony formation
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Discussion
Our findings demonstrated that copy number gain of Yes1, which encodes Src family protein
Yes1, was a mechanism of the acquired resistance to trastuzumab and lapatinib. As lapatinib is
used in the situation of the acquired resistance to trastuzumab in HER2-positive breast cancers
clinically, we established a trastuzumab/lapatinib-dual resistant cell line (BT-474-RL2) from
trastuzumab-resistant cell line (BT-474-R). Of interest, Yes1 copy number was more increased
in BT-474-RL2 compared to BT-474-R, resulting in further increased mRNA and protein
expression of Yes1 in BT-474-RL2. Src family proteins are non-receptor tyrosine kinases, and
are reported to accelerate cell proliferation by the reciprocal activation with RTKs such as
HER2, and activating PI3K/Akt and MAPK pathways [16, 27]. Src is considered as an
assay in BT-474-R and BT-474-RL2. Data are shown as means + SE. The assay was repeated three times. (D)
phosphorylation status of HER2 and Akt upon treatment with trastuzumab alone, dasatinib alone or the
combination of them for 1 hour in BT-474, BT-474-R and BT-474-RL2.
doi:10.1371/journal.pone.0171356.g004
Fig 5. Combination of trastuzumab and dasatinib induce cell-cycle arrest in G1 phase and apoptosis. (A) Upper: Cell cycle analysis
of BT-474-R upon treatment with trastuzumab alone, dasatinib alone or combination of them. Lower: G0-G1 population in BT-474, BT-
474-R and BT-474-RL2. Data are shown as means + SE. The assay was repeated three times. (B) Apoptosis analysis by the detection of
PARP cleavage in western blot analysis in BT-474, BT-474-R and BT-474-RL2.
doi:10.1371/journal.pone.0171356.g005
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oncogene, as it is reported to be dysregulated in breast and colorectal cancers [28, 29]. It is
reported that the activation of Src family proteins is associated with the acquired resistance to
trastuzumab in gastric cancer [30]. Src family proteins are also reported to be associated with
the resistance to lapatinib [31]. Src family proteins include c-Src Yes, Fyn, Lyn, Fgr, Blk, Hck,
Lck, and Frk [32]. Thus, we further analyzed which Src protein was related with the mecha-
nism of the resistance to trastuzumab and lapatinib, resulting in the clarification of aberrant
expression of Yes1. Knockdown of Yes1 resulted in the recovery of the sensitivity to trastuzu-
mab and lapatinib, indicating that Yes1 was the key molecule to overcome the resistance to
trastuzumab and lapatinib.
There are many works elucidating the resistance mechanisms of trastuzumab, and several
mechanisms were reported. Even in the case that the same cell line, BT-474, is used, different
mechanisms have been reported. For example, we had found that nuclear factor-kappa B (NF-
kappaB) was constitutively activated in the BT-474-R cells [23]. In the process of acquiring the
resistance, several different molecular alterations may emerge depending on the culture condi-
tion in vitro and microenviromental conditions in vivo. We previously reported that drug con-
centration in the process of establishing the resistant cells to gefitinib contributed to the
different causative alterations in the acquired resistant clones derived from the same parental
cancer cell lines [33]. In the current study, our experimental results documented that Src fam-
ily Yes1 was responsible to the resistance. Because Src has already been reported as the resis-
tance mechanism of trastuzumab [16, 17], we consider that Src signaling plays a pivotal role in
the acquired resistance to trastuzumab.
We focused on dasatinib, which is known to be a Src inhibitor and is used for targeting
BCL-ABL fusion protein in chronic myelocytic leukemia and for targeting Philadelphia chro-
mosome in acute lymphatic leukemia [34]. Dasatinib also targets Yes1 [35]. One of the strategy
to conquer the resistance to a certain drug targeting driver alteration is the combination
Fig 6. Effect of the Yes1 mRNA expression on prognosis in HER2-positive breast cancer patients. (A) In TP53 cohort
(GSE3494) with higher expression of HER2, disease-specific survival (DSS) of the cases with higher Yes1 mRNA expression was
significantly shorter than that of the cases with lower expression of Yes1 (P = 0.0133). (B) In metastasis cohort (GSE12276) with
higher expression of HER2, relapse free survival (RFS) of the cases with higher expression of Yes1 was significantly shorter than that
of the cases with lower expression of Yes1 (P = 0.0000546).
doi:10.1371/journal.pone.0171356.g006
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treatment of the drug targeting driver alteration and the one targeting the mechanism of the
resistance to driver alteration. For example, MET amplification can be detected after the treat-
ment of the first generation of EGFR-tyrosine kinase inhibitor (EGFR-TKI), gefitinib or erloti-
nib, in EGFR-mutant lung adenocarcinomas, and the combination of EGFR-TKI and MET
inhibitor is demonstrated to be an effective treatment [36]. In the current study, dasatinib plus
trastuzumab or lapatinib showed additive anti-tumor effect to BT-474-R and BT-474-RL2,
although dasatinib alone had an enough anti-tumor effect to the cells resistant to trastuzumab
or lapatinib. Acquired resistance of cancer cells to a drug targeting the driver alteration can be
mediated by a switch to the dependency on a certain molecule [37, 38]. In the acquisition of
the resistance to trastuzumab/lapatinib, there is a possibility that a switch to Yes1 was induced
to breast cancer cells depending on HER2 for proliferation, as dasatinib alone had an enough
power to treat the resistant cells. Regarding the discrepancy of the results between Fig 4A and
4B, we consider that the difference of the drug exposure time may influence the results. Fig 4A
shows the result of cell viability assay, in which the cells were exposed to drugs for 72 hours.
On the other hand, the cells were exposed to the drugs for 14 days in clonogenic assay shown
in Fig 4B. Additionally, these two types of assays measure different properties of cancer cells.
Cell viability assay using MTS are set up at higher cell densities in the plate and cell prolifera-
tion in the presence of the range of drug concentration is measured. On the other hand, clono-
genic assay measures clonogenicity of cancer cells, which involves different signaling
pathways. As for another reason why dasatinib alone showed the inhibitory effect of cell prolif-
eration to the resistant cell lines compared to the Yes1-specific inhibition by siRNA, we con-
sider that dasatinib is a multi-kinase inhibitor, and thus dasatinib inhibits not only Src family
member proteins but also BCR/ABL, c-Kit, EPHA2 receptors, and PDGF beta receptors,
which might partially contribute on cell survival, resulting in the inhibitory effect. Although
Src inhibitor saracatinib was reported to overcome the resistance mechanism [16, 30], saracati-
nib is not applied to clinical setting at the present moment. On the other hand, dasatinib has
already been used in clinical setting and it can be applied to the treatment to conquer the resis-
tance to trastuzumab and lapatinib.
We also conducted in vivo analysis after injecting BT-474, BT-474-R to severe combined
immunodeficiency (SCID) mice. However, BT-474-R did not show enough resistance to tras-
tuzumab in vivo (S2 Fig). This is considered due to antibody-dependent-cellular-cytotoxicity
(ADCC) in SCID mice [39]. As for BT-474-RL2, tumor formation in SCID mice was not
enough to perform in vivo analysis.
To elucidate the impact of Yes1 expression on the prognosis in HER2-positive breast cancer
patients, we performed bioinformatics analysis using two different cohorts. Higher Yes1
expression was correlated with worse prognosis in HER2-positive breast cancer patients.
Although the poor prognostic factor is not strictly equivalent to the resistance mechanism to
trastuzumab, the results from clinical data support that Yes1 has a pivotal role in HER2-posi-
tive breast cancer.
In resistant cell lines, the phosphorylation of HER2 and Akt was upregulated in addition to
Yes1, whereas phospho-MAPK was downregulated, implying that MAPK signaling might be
inhibited by the negative feedback due to the activation of PI3K/Akt pathway. To understand
this result, a further study is necessary.
In conclusion, we found that Yes1 is a key molecule for the resistance mechanism of trastu-
zumab and lapatinib in a certain population of HER2-positive breast cancers. Further investi-
gation is warranted to clarify the mechanism of the acquired resistance to trastuzumab and
lapatinib and for the therapeutic strategy to overcome the resistance.
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Supporting information
S1 Fig. Blk, Fgr and Hck are highly expressed in lymphoma cell lines. Blk and Fgr were
expressed in Burkitt’s lymphoma cell line Daudi, whereas Hck was expressed in histiocytic
lymphoma cell line U937. However, these genes were not expressed in BT-474, BT-474-R or
BT-474-RL2.
(TIF)
S2 Fig. Growth of BT-474 and BT-474-R in SCID mice. The animals were treated with vehi-
cle or 2 mg/kg trastuzumab once per week (arrows). Data are shown as means ± standard devi-
ation (SD) (n = 4).
(TIF)
S3 Fig. Original data of western blot analysis in Figs 2–5 and RT-PCR in S1 Fig. Original
data of western blot analysis and RT-PCR is provided.
(PDF)
S1 Method. Methods for “mRNA expression of Blk, Fgr and Hck” and “Animal xenograft
mouse model”. Detailed methods are described.
(DOCX)
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